EGFR and non-small cell lung carcinoma: Although not specifically focused on patients with EGFR mutations, the NCT04691817 trial is currently enrolling participants to evaluate the safety and efficacy of tocilizumab, a monoclonal antibody targeting the IL-6 receptor, in combination with atezolizumab, for the treatment of NSCLC.